-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1768 The Risk of Cerebrovascular Accident in Patients with Myelodysplastic Syndrome in the United States: A Nationwide Population-Based Study

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Acquired Marrow Failure Syndromes, adult, Bone Marrow Failure Syndromes, Clinical Research, Diseases, real-world evidence, thrombotic disorders, Study Population, Human
Saturday, December 10, 2022, 5:30 PM-7:30 PM

Dina Elantably, MD1*, Jiasheng Wang, MD2, Abdul Rahman Al Armashi, MD2*, Nabil El Hage Chehade, MD1* and Akram Alkrekshi, MD3*

1Department of Internal Medicine, Case Western Reserve University MetroHealth Medical Center, Cleveland, OH
2Department of Hematology and Oncology, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH
3Department of Internal Medicine, Case Western Reserve University MetroHealth Medical Center, Westlake, OH


The natural history of myelodysplastic syndrome (MDS) is often complicated by thrombosis and hemorrhages due to quantitative and qualitative platelet anomalies. However, there is a dearth of real-world data regarding the risk of cerebrovascular accident (CVA) in the setting of MDS. This study focuses on assessing the risk of CVA among patients with MDS in the United States.


A retrospective study was performed using a large commercial US-based population database (Explorys, IBM) that aggregates records from 26 healthcare systems and includes over 80 million patients. Using Systematized Nomenclature of Medicine- Clinical Terms (SNOMED-CT), we identified adult patients (over 18 years old) diagnosed with MDS between 1999 and 2022. We examined the risk of CVA in these patients. Multivariable logistic regression was used to adjust for known variables associated with CVA such as sex, age > 65, hypertension (HTN), hyperlipidemia (HLD), diabetes mellitus (DM), tobacco use, atrial fibrillation (Afib), and the use of erythropoiesis-stimulating agents (ESA).


A total of 70,502,300 patients were included in the analysis. 54, 950 patients were diagnosed with MDS; 53% were males, 84% were above the age of 65, 75% had underlying hypertension, 61% had hyperlipidemia, 36% had diabetes mellitus, 11% were smokers, and 31% had underlying atrial fibrillation (Table 1). The incidence of CVA during the study period among patients with MDS was 1.4%. After adjusting for possible confounding factors (Table 2), MDS was independently associated with a 1.47-fold increased risk of developing CVA (OR 1.47; 95% CI 1.39-1.54; P<0.001), compared with those without MDS. The risk of CVA was also significantly higher with the use of erythropoietin stimulating agents (OR 1.46; 95% CI 1.43-1.49, P<0.001).


This large real-world study demonstrated that MDS was an independent risk factor for CVA. With 47% higher odds, the risk is almost comparable to tobacco use. The use of erythropoiesis-stimulating agents in patients with MDS was another independent risk factor. The exact pathophysiology by which MDS increases the risk of arterial thrombosis has not yet elucidated. Further studies are needed to illustrate the possible underlying mechanisms which may lead to early interventions to decrease morbidity and mortality in this group of patients.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH